Show simple item record

dc.contributor.authorSeravalli, E
dc.contributor.authorKroon, PS
dc.contributor.authorBuatti, JM
dc.contributor.authorHall, MD
dc.contributor.authorMandeville, HC
dc.contributor.authorMarcus, KJ
dc.contributor.authorOnal, C
dc.contributor.authorOzyar, E
dc.contributor.authorPaulino, AC
dc.contributor.authorPaulsen, F
dc.contributor.authorSaunders, D
dc.contributor.authorTsang, DS
dc.contributor.authorWolden, SL
dc.contributor.authorJanssens, GO
dc.date.accessioned2021-09-21T13:30:40Z
dc.date.available2021-09-21T13:30:40Z
dc.identifier.citationClinical and translational radiation oncology, 2021, 29 pp. 71 - 78
dc.identifier.issn2405-6308
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4818
dc.identifier.eissn2405-6308
dc.identifier.doi10.1016/j.ctro.2021.05.008
dc.description.abstractBackground and purpose Magnetic resonance guided radiotherapy (MRgRT) has been successfully implemented for several routine clinical applications in adult patients. The purpose of this study is to map the potential benefit of MRgRT on toxicity reduction and outcome in pediatric patients treated with curative intent for primary and metastatic sites.Materials and methods Between May and August 2020, a survey was distributed among SIOPE- and COG-affiliated radiotherapy departments, treating at least 25 pediatrics patients annually and being (candidate) users of a MRgRT system. The survey consisted of a table with 45 rows (clinical scenarios for primary (n = 28) and metastatic (n = 17) tumors) and 7 columns (toxicity reduction, outcome improvement, PTV margin reduction, target volume daily adaptation, online re-planning, intrafraction motion compensation and on-board functional imaging) and the option to answer by 'yes/no' . Afterwards, the Dutch national radiotherapy cohort was used to estimate the percentage of pediatric treatments that may benefit from MRgRT.Results The survey was completed by 12/17 (71% response rate) institutions meeting the survey inclusion criteria. Responders indicated an 'expected benefit' from MRgRT for toxicity/outcome in 7% (for thoracic lymphomas and abdominal rhabdomyosarcomas)/0% and 18% (for mediastinal lymph nodes, lymph nodes located in the liver/splenic hilum, and liver metastases)/0% of the considered scenarios for the primary and metastatic tumor sites, respectively, and a 'possible benefit' was estimated in 64%/46% and 47%/59% of the scenarios. When translating the survey outcome into a clinical perspective a toxicity/outcome benefit, either expected or possible, was anticipated for 55%/24% of primary sites and 62%/38% of the metastatic sites.Conclusion Although the benefit of MRgRT in pediatric radiation oncology is estimated to be modest, the potential role for reducing toxicity and improving clinical outcomes warrants further investigation. This fits best within the context of prospective studies or registration trials.
dc.formatElectronic-eCollection
dc.format.extent71 - 78
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleThe potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey.
dc.typeJournal Article
dcterms.dateAccepted2021-05-24
rioxxterms.versionNA
rioxxterms.versionofrecord10.1016/j.ctro.2021.05.008
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical and translational radiation oncology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Paediatric and Adolescent Radiotherapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Paediatric and Adolescent Radiotherapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume29
pubs.embargo.termsNot known
icr.researchteamPaediatric and Adolescent Radiotherapy
icr.researchteamPaediatric and Adolescent Radiotherapyen_US
dc.contributor.icrauthorMandeville, Henryen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0